Leda Health Corporation v. Inslee

CourtDistrict Court, W.D. Washington
DecidedOctober 21, 2024
Docket2:24-cv-00871
StatusUnknown

This text of Leda Health Corporation v. Inslee (Leda Health Corporation v. Inslee) is published on Counsel Stack Legal Research, covering District Court, W.D. Washington primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Leda Health Corporation v. Inslee, (W.D. Wash. 2024).

Opinion

1 2 3 4 5

6 7 UNITED STATES DISTRICT COURT 8 WESTERN DISTRICT OF WASHINGTON AT TACOMA 9 10 LEDA HEALTH CORPORATION, CASE NO. 2:24-cv-00871-DGE 11 Plaintiff, ORDER ON MOTION FOR 12 v. PRELIMINARY INJUNCTION (DKT. NO. 10), MOTION TO 13 JAY ROBERT INSLEE et al., DISMISS (DKT. NO. 30), AND MOTION FOR EVIDENTIARY 14 Defendant. HEARING (DKT. NO. 34) 15

16 I INTRODUCTION 17 This matter comes before the Court on Plaintiff’s motion for a preliminary injunction 18 (Dkt. No. 10) and Defendants’ motion to dismiss for failure to state a claim (Dkt. No. 30). 19 Defendants filed a response to Plaintiff’s motion for injunctive relief (Dkt. No. 18), to which 20 Plaintiff replied (Dkt. No. 29). Plaintiff subsequently filed a motion for an evidentiary hearing 21 (Dkt. No. 34), to which Defendants responded (Dkt. No. 36), Plaintiff replied (Dkt. No. 39), and 22 Defendant surreplied (Dkt. No. 40). Plaintiff then filed a response to Defendants’ motion to 23 dismiss (Dkt. No. 37), to which Defendant replied (Dkt. No. 41). Upon careful consideration of 24 1 the briefing filed by both parties, the Court concludes this matter is suitable for disposition 2 without oral argument. See LCR 7(b)(4); United States v. State of Or., 913 F.2d 576, 582 (9th 3 Cir. 1990) (“[W]e have rejected any presumption in favor of evidentiary hearings[.]”). 4 The Court DENIES Plaintiff’s motion for a preliminary injunction and GRANTS 5 Defendants’ motion to dismiss for the reasons set forth below. Accordingly, Plaintiff’s motion

6 for an evidentiary hearing is DENIED as moot, and Defendants’ surreply is also moot. 7 II BACKGROUND 8 A. Factual Background 9 Leda Health is a company known for developing Early Evidence Kits (“EEKs”)— 10 products that allegedly enable sexual assault survivors to “self-collect and store evidence such as 11 DNA” if they are unable or unwilling to seek a traditional forensic medical examination. (Dkt. 12 No. 11 at 4.) Each EEK is branded with a unique barcode and contains an instruction manual on 13 DNA self-collection, diagnostic swabs, sterile water for swabbing dry areas, a prepaid FedEx bag 14 for shipping to an accredited partner lab, tamper-evident tape, plastic bags for storing clothing or

15 other relevant items, and an intake form for documenting the assault and chain of custody. (Id. at 16 6.) Leda sells its EEKs to companies or other entities with which it partners—including sorority 17 chapters on college campuses. (Id. at 5.) In 2022, Leda attempted to partner with the University 18 of Washington’s Kappa Delta sorority. (Id. at 4.) 19 On October 31, 2022, the Washington State Attorney General’s Office (AGO) issued 20 Leda a cease-and-desist notification. The letter directed Leda to “immediately cease and desist 21 from advertising, marketing, and sales to Washington consumers related to its ‘Early Evidence 22 Kits’ on the basis that Leda’s business practices related to these kits violated the Washington 23 Consumer Protection Act.” (Dkt. No 19-1 at 29.) The letter stated that “Leda’s claims regarding 24 1 the admissibility of its at-home kits have the capacity to deceive a Washington consumer into 2 believing that its Early Evidence Kits have equivalent evidentiary value to a sexual assault 3 evidence kit (“SAEK”) administered by a medical professional.” (Id. at 30). The notice went on 4 to assert that the self-administered nature of Leda’s EEKs would predictably result in “numerous 5 barriers to admission as evidence, including on the basis of potential cross-contamination,

6 spoilation, and validity.” (Id.) It emphasized that, in Washington, exams by a trained Sexual 7 Assault Nurse Examiner (SANE) are “both free and routinely admissible.” (Id. at 31.) Thus, the 8 letter concluded that “Leda charging consumers for Early Evidence Kits despite the fact they are 9 unlikely to be admissible in a criminal court is an unfair and deceptive business practice” in 10 violation of the Washington Consumer Protection Act. (Id.) 11 Washington was not the first state to raise concerns about the emergence of at-home 12 sexual assault evidence collection kits. In 2019, Attorneys General from New York, Oklahoma, 13 Connecticut, Michigan, North Carolina, Hawaii, and Florida sent cease and desist notifications to 14 Leda’s precursor company, MeToo Kits. (See Dkt. No. 19-1 at 35–67.) In 2020, New

15 Hampshire’s legislature passed a bill establishing that “[n]o person shall sell or offer for sale in 16 the state of New Hampshire an over-the-counter rape test kit.” N.H. Rev. Stat. § 359-R:1. 17 Washington and Maryland1 followed New Hampshire’s lead. 18 On January 24, 2023, Washington’s legislature first considered House Bill 1564: “An Act 19 Relating to prohibiting the sale of over-the-counter sexual assault kits.” (Dkt. No. 19-1 at 3.) 20 After multiple hearings, the bill was passed and went into effect on July 23, 2023. (Dkt. No. 30 21 at 13.) Several representatives from Leda Health testified at the hearings, asserting that Leda’s 22

23 1 See Md. Code Ann. Com. Law § 14-4602 - Sale, offer for sale, or distribution of a self- administered sexual assault kit prohibited. 24 1 kits are not misleading but rather intended to be an additive option for the approximately 70% of 2 sexual assault victims who do not go to the hospital, or for those who go but are not able to see a 3 SANE nurse. (Dkt. No. 13 at 181.) Leda further stated that while the company did not guarantee 4 evidence admissibility, it had procedures in place to establish chain of custody and believed that 5 evidence from its kits should be admissible in court. (Id.) Nevertheless, the legislature found

6 that “[a]t-home sexual assault test kits create false expectations and harm the potential for 7 successful investigations and prosecutions.” 2023 Wash. Sess. Laws, ch. 296, § 1. Thus, it 8 concluded “[t]he sale of over-the-counter sexual assault kits may prevent survivors from 9 receiving accurate information about their options and reporting processes; from obtaining 10 access to appropriate and timely medical treatment and follow up; and from connecting to their 11 community and other vital resources.” Id. Entitled “[o]ver-the-counter sexual assault kits” and 12 codified at Washington Revised Code § 5.70.070, the act establishes that: 13 (2) A person may not sell, offer for sale, or otherwise make available a sexual assault kit:

14 a) That is marketed or otherwise presented as over-the-counter, at-home, or self-collected or in any manner that indicates that the sexual assault kit may 15 be used for the collection of evidence of sexual assault other than by law enforcement or a health care provider; or 16 b) If the person intends, knows, or reasonably should know that the sexual 17 assault kit will be used for the collection of evidence of sexual assault other than by law enforcement or a health care provider. 18 Wash. Rev. Code § 5.70.070(2). The statute defines “sexual assault kit” as “a product with 19 which evidence of sexual assault is collected.” Wash. Rev. Code § 5.70.070(1). It further 20 stipulates that a violation of the section constitutes “an unfair or deceptive act in trade or 21 commerce and an unfair method of competition for the purpose of applying [Washington’s] 22 consumer protection act.” Wash. Rev. Code § 5.70.070(3). 23 B.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Citizens United v. Federal Election Commission
558 U.S. 310 (Supreme Court, 2010)
United States v. Lovett
328 U.S. 303 (Supreme Court, 1946)
United States v. Brown
381 U.S. 437 (Supreme Court, 1965)
United States v. O'Brien
391 U.S. 367 (Supreme Court, 1968)
United States v. Mazurie
419 U.S. 544 (Supreme Court, 1975)
Elrod v. Burns
427 U.S. 347 (Supreme Court, 1976)
Nixon v. Administrator of General Services
433 U.S. 425 (Supreme Court, 1977)
Hoffman Estates v. Flipside, Hoffman Estates, Inc.
455 U.S. 489 (Supreme Court, 1982)
Weinberger v. Romero-Barcelo
456 U.S. 305 (Supreme Court, 1982)
Bolger v. Youngs Drug Products Corp.
463 U.S. 60 (Supreme Court, 1983)
Arcara v. Cloud Books, Inc.
478 U.S. 697 (Supreme Court, 1986)
Amoco Production Co. v. Village of Gambell
480 U.S. 531 (Supreme Court, 1987)
United States v. Salerno
481 U.S. 739 (Supreme Court, 1987)
Edenfield v. Fane
507 U.S. 761 (Supreme Court, 1993)

Cite This Page — Counsel Stack

Bluebook (online)
Leda Health Corporation v. Inslee, Counsel Stack Legal Research, https://law.counselstack.com/opinion/leda-health-corporation-v-inslee-wawd-2024.